

Please amend the application as follows:

In the Claims:

Cancel claims 1-3, 6-27 and 30-31.

Amend as follows:

AI SUB B1 4. (amended) A method of treating a staphylococcal infection of at least one organ or tissue selected from the group consisting of heart valve, blood, kidney, lung, bone and meninges, comprising [selecting a mammal suffering from at least one of said disease conditions; and] administering to [the] a mammal suffering from at least one of said infections an effective amount of [a] at least one recombinantly produced lysostaphin analogue.

5. (amended) A method of treating a staphylococcal infection associated with a catheter or a prosthetic device, comprising [selecting a mammal suffering from such an infection; and] administering to [the] a mammal suffering from such an infection an effective amount of [a] at least one recombinantly produced lysostaphin analogue.

A2 SUB B2 28. (amended) A therapeutic composition for the treatment of staphylococcal infection, comprising [a] at least one recombinantly produced lysostaphin analogue having the biological activity of proteolytic attack against glycine-containing bridges in the cell wall peptidoglycan of staphylococci and a pharmaceutically acceptable carrier.

Add the following claims:

A3 SUB C2 --32. The method of claim 4 or 5 wherein the lysostaphin analogue(s) is/are administered together with at least one rifamycin or glycopeptide or combination thereof.

33. The method of claim 4 or 5 wherein the lysostaphin analogue(s) is/are administered in multiple doses per day.

34. The method of claim 32 wherein the lysostaphin analogue(s) is/are administered in multiple doses per day. 2

53 33 35. The composition of claim 28 or 29 further comprising at least one rifamycin or glycopeptide or combination thereof. 2

36. The method of claim 4 or 5 wherein the lysostaphin analogue(s) is/are administered in an amount not to exceed 50 mg/kg per dose. 2

37. The method of claim 32 wherein the lysostaphin analogue(s) is/are administered in an amount not to exceed 50 mg/kg per dose. 2

38. The method of claim 33 wherein the lysostaphin analogue(s) is/are administered in an amount not to exceed 50 mg/kg per dose. 2

39. The method of claim 34 wherein the lysostaphin analogue(s) is/are administered in an amount not to exceed 50 mg/kg per dose. 2

40. The method of claim 4 or 5 wherein the amount of lysostaphin analogue(s) administered is between 0.5 mg/kg/day and 200 mg/kg/day. 2

41. The method of claim 32 wherein the amount of lysostaphin analogue(s) administered is between 0.5 mg/kg/day and 200 mg/kg/day. 2

42. The method of claim 33 wherein the amount of lysostaphin analogue(s) administered is between 0.5 mg/kg/day and 200 mg/kg/day. 2

53 33 43. The method of claim 34 wherein the amount of lysostaphin analogue(s) administered is between 0.5 mg/kg/day and 200 mg/kg/day. 2

44. The method of claim 40 wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 50 mg/kg/day. 2

45. The method of claim 41 wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 50 mg/kg/day. 2

46. The method of claim 42 wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 50 mg/kg/day. 2

47. The method of claim 43 wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 50 mg/kg/day. 2

48. The method of claim 44 wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 25 mg/kg/day. 2

49. The method of claim 45 wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 25 mg/kg/day. 2

50. The method of claim 46 wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 25 mg/kg/day. 2

51. The method of claim 47 wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 25 mg/kg/day. 2

52. The method of claim 4 or 5 wherein the amount of lysostaphin analogue(s) administered is no more than 45 mg/kg/day. 2

53. The method of claim 32 wherein the amount of lysostaphin analogue(s) administered is no more than 45 mg/kg/day. 2

54. The method of claim 33 wherein the amount of lysostaphin analogue(s) administered is no more than 45 mg/kg/day. 2

55. The method of claim 34 wherein the amount of lysostaphin analogue(s) administered is no more than 45 mg/kg/day.-- 2

REMARKS

Claims 1-3, 6-27 and 30-31 have been canceled. Claims 4-5 and 28 have been amended.

Claims 32-55 have been added. Thus, claims 4-5, 28-29 and 32-55 are now pending.